U.S. patent application number 12/295139 was filed with the patent office on 2011-04-21 for method for treating/preventing disease using cognitive ability of cerebrum and pharmaceutical.
Invention is credited to Takuro Minowada.
Application Number | 20110092548 12/295139 |
Document ID | / |
Family ID | 38540917 |
Filed Date | 2011-04-21 |
United States Patent
Application |
20110092548 |
Kind Code |
A1 |
Minowada; Takuro |
April 21, 2011 |
METHOD FOR TREATING/PREVENTING DISEASE USING COGNITIVE ABILITY OF
CEREBRUM AND PHARMACEUTICAL
Abstract
An object of the present invention is to develop a method of
enhancing the cognitive ability of a brain to fundamentally cure a
disease. It has been found out that, by using a medicament for
treating or preventing a disease including a combination of a major
tranquilizer, and vitamin C or a salt thereof and, if necessary,
drip infusion, an antidepressant and an iron agent, the cognitive
ability of a brain is enhanced, thus, an arbitrary disease
including various cancers can be treated. The present invention
also provides a method for treating or preventing a disease
including a step of administering a major tranquilizer, and vitamin
C or a salt thereof to a subject suffering from the disease.
Inventors: |
Minowada; Takuro; (Sakyo-ku,
JP) |
Family ID: |
38540917 |
Appl. No.: |
12/295139 |
Filed: |
July 21, 2006 |
PCT Filed: |
July 21, 2006 |
PCT NO: |
PCT/JP2006/314530 |
371 Date: |
January 9, 2009 |
Current U.S.
Class: |
514/345 |
Current CPC
Class: |
A61K 31/15 20130101;
A61K 9/2018 20130101; A61K 31/4515 20130101; A61K 9/0085 20130101;
A61K 31/197 20130101; A61P 25/14 20180101; A61K 31/4523 20130101;
A61P 35/00 20180101; A61K 9/19 20130101; A61K 31/375 20130101; A61K
33/26 20130101; A61P 21/00 20180101; A61K 9/0019 20130101; A61P
35/02 20180101; A61K 31/00 20130101; A61P 21/04 20180101; A61K
45/06 20130101 |
Class at
Publication: |
514/345 |
International
Class: |
A61K 31/451 20060101
A61K031/451; A61P 35/00 20060101 A61P035/00 |
Foreign Application Data
Date |
Code |
Application Number |
Mar 29, 2006 |
JP |
2006-091370 |
Claims
1. A method for treating or preventing cancer, comprising
administering to a patient in need thereof an effective amount of
haloperidol, vitamin C or a salt thereof, fluvoxamine maleate, and
sodium ferrous citrate, wherein: the haloperidol is administered at
a daily dose of 0.25 mg to 1 mg; the vitamin C is administered at a
daily dose of 600 mg to 1800 mg; and the fluovoxamine maleate is
administered when blood potassium is decreased.
2-6. (canceled)
7. The method according to claim 1, wherein the vitamin C is
ascorbic acid which is an artificial substance.
8. (canceled)
9. The method according to claim 1, further combined with drip
infusion.
10. The method according to claim 1, wherein the drip infusion is a
physiological buffer containing maltose.
11-17. (canceled)
18. The method according to claim 9, wherein the drip infusion is
administered until appetite is worked up.
19. The method according to claim 1, wherein the haloperidol is
administered before bedtime.
20-22. (canceled)
23. The method according to claim 1, wherein the vitamin C is
further combined with pantothenic acid or a salt thereof.
24-25. (canceled)
26. The method medicament-according to claim 1, wherein the cancer
is selected from large intestine cancer, colon cancer, rectum
cancer, thyroid cancer, esophagus cancer, chorionic cancer,
gallbladder cancer, neuroblastoma, maxillary cancer, oral cavity
cancer, genitourinary cancer, malignant lymphoma, liver cancer,
prostate cancer, lung cancer, lung cell cancer, breast cancer,
stomach cancer, bladder cancer, pancreas cancer, testis cancer,
uterus cancer, corpus uteri cancer, cervix uteri cancer, ovary
cancer, pharynx cancer, myelocytic leukemia, brain tumor, biliary
cancer, neuroblasto tumor, melanocytoma, gastrinoma, insulinoma,
carcinoid, kidney cancer, testicular cancer, adult T cell leukemia,
vagina cancer, vulva cancer, skin cancer, upper airway cancer, head
and neck cancer, teratoma, gallbladder cancer, acute myelocytic
leukemia, acute lymphatic leukemia, malignant lymphoma, sarcoma,
malignant melanoma, lymphoma, lung squamous epithelium cancer and
spinocerebellar degeneration.
27-30. (canceled)
31. Use of a combination of haloperidol, vitamin C or a salt
thereof, fluvoxamine maleate, and sodium ferrous citrate, in the
manufacture of a medicament for treating or preventing cancer,
wherein: the haloperidol is administered at a daily dose of 0.25 mg
to 1 mg; the vitamin C is contained so that it is administered at a
daily dose of 600 mg to 1800 mg as an effective amount; and the
fluovoxamine maleate is administered when blood potassium is
decreased.
32. The use according to claim 31, wherein the combination further
comprises a drip infusion.
33-38. (canceled)
39. The method according to claim 1, wherein the fluovoxamine
maleate is administered at an amount of 25 mg or 50 mg.
Description
TECHNICAL FIELD
[0001] The present invention relates to a method and a medicament
for treating or preventing a disease. More particularly, the
present invention relates to a method and a medicament for treating
or preventing a disease using cognition of the cerebrum.
BACKGROUND ART
Structure of Brain
[0002] A structure of a brain is said to be most mysterious in this
universe. A human brain is classified into cerebrum and cerebellum.
Simply speaking, cerebrum is apart which controls the psychiatric
function, and cerebellum is a part which controls balance sense.
When these two are compared, the weight of cerebellum is around 11%
of a whole brain, and cerebrum accounts for a major part. When a
longitudinal cross-section of a brain is observed, in the center,
there are diencephalon, mesencephalon, and medulla oblongata, and
medulla oblongata which is continuous with spinal cord.
[0003] (Is a Brain Heavy?!)
[0004] To say a weight of a whole brain, it is about 1450 gram in
men, and is about 1300 gram, a little bit lighter in women. Does
the difference in the brain weight mean that women are less wise
than men? The answer is no. It has been known that wisdom does not
depend on the brain weight. Meanwhile, there is a concern that if a
person having such a heavy head at the top of the body has such a
heavy thing placed on the head, this person might have stiff
shoulders, but this is not true. A brain is protected with a triple
membrane consisting of dura mater, arachnoid mater and pia mater in
this order from the outside, and an about one cup of spinal fluid
is filled between the arachnoid mater and the pia mater. By walking
upright with two feet, a brain is supported by a spinal column
which is in an appropriately vertical position, and an actual brain
weight is not felt.
[0005] (Wrinkle of Brain)
[0006] If it is concluded that a weight of a brain has no
relationship with the wisdom, what is related to the wisdom? As is
frequently said from old times, there is another opinion that a
person whose brain has many wrinkles is wise. A human brain has, if
getting rid of wrinkles, a 2250 square centimeter area, that is, a
size of one side of a newspaper. It can also be said that the
wrinkles had to be folded and stored without a choice to place such
a large-size brain into a narrow skull bone.
[0007] Therefore, it can be said that a wrinkle indicates a folding
part. Two thirds of a surface area of a human brain is hidden in a
groove of this wrinkle, and can not be seen from the outside. What
can be said regarding a wrinkle is only that the relationship
between a surface area when wrinkles of the brain is removed and a
size of a container for a brain determines the number of
wrinkles.
(Network of Nerve Cell)
[0008] When it is concluded, as described above, that neither a
weight nor a wrinkle is related to the wisdom, what is a
determinant factor? A possible answer is the number and the
function of brain nerve cells. Meanwhile, the number of nerve cells
of a human brain is said to be 14 billion in total, and when were a
total of 14 billion nerve cells generated? Surprisingly, it is
known that 14 billion nerve cells have already been generated at
birth, same as in an adult, all equally.
[0009] In principle, a nerve cell is not divided. Assuming that
there are a total of 14 billion nerve cells, all of the 14 billion
nerve cells seem to be necessary for the balance or stabilization
in a skull bone. Dr. Takeshi Yoro (former professor of the
Institute of Brain Research, the University of Tokyo) reported
that, even when a certain part of nerve cells get injured, a human
can live a normal life with only 3% of nerve cells. It is also
reported that, even when a certain part gets damaged, intact
neurons replace for it over a long time.
[0010] When a shape of a nerve cell is seen, many prickle-like
materials are projected from a nerve cell. Normally, there are a
few tens of prickles, and only one long prickle among them is
called nerve fiber. It is shaped like a connected Vienna sausages
and has a bulging part at the end. This is called terminal button.
The button attaches to a adjacent or peripheral nerve cell. They
are not fused into each other but merely lapped and adhered. The
more binding formats there are, the better results occur, that is,
a brain in which larger number of this network of nerve cells is
generated more closely results in the wisdom.
[0011] (Formation of Network)
[0012] Entanglement of the nerve cells grows frequently three
months after birth. It is said that, at 15 months, the entanglement
becomes more complicated and, at about 3 years old to 4 years old,
the development of a fundamental network is completed. A size of a
brain becomes about 4-fold bigger at around 4 year old than at
birth, approximately the same size as an adult. For this reason,
the environment in childhood is important.
[0013] (Team Work of Brain)
[0014] A human memorizes many things every day. It is said that a
brain has 14 billion nerve cells, and in which part of a brain the
memorization is performed becomes a question. It has been known
that memorization is performed in a head front (frontal cortex)
which is present at a font part of a head, and in this part, the
human behaviors such as creating a thing or thinking is conducted.
In addition, a vertex of a head has relationship mainly with
movement, and a side part of a head is responsible for memory,
judgment, acoustic sense, and language. A rear part of a head
controls an eye just situated on the other side of the head (visual
sense). Like this, each part of cerebrum works separately. This
separate work is not performed disorderly, but each part helps each
other, and co-operates, thus, an organization play is conducted
considerably well. For this reason, when a separate working system
is well established, the brain works well (FIG. 1).
[0015] (Nerve Cells of a Brain are Decreasing)
[0016] Sixty to eighty thousand nerve cells of a brain are dying
every day, and as a human is getting older, the number of destroyed
nerve cells is increased. Since the nerve cell is not regenerated,
nerve cells are decreasing without stopping. From the age of about
40, the decrease becomes remarkable. It is said that, from
calculation, the nerve cell becomes zero at the age of 230. It is
said that 200 thousand cells are lost every day around the age of
over 40, and the number of lost cells becomes about 73 million per
year. However, this seems trivial.
[0017] Japanese psychiatric medicine is directed to psychiatric
analytical methodology too much, and is substantially delayed in
study involving the function and the structure of cerebrum or
positioning of those psychiatric medicines in the clinic setting.
From now on, such region must be studied more vigorously. Now,
let's discuss on the function of a brain by exemplifying an easily
understandable example.
[0018] We see objects or the surrounding situation through eyes
every day, but we don't always actually "see" all things that meet
eyes. When we see a face of a person, even if there is a vase
behind the person, we do not "see" the vase.
[0019] However, it is not considered that such the selection is
conducted by the central function of visual sense.
[0020] Alternatively, when we are chatting with a person,
accompanying a content of a conversation, past memory is recalled,
or new presumption or imagination is generated. In such a case, no
one think that such association is generated in a center of an
acoustic sense.
[0021] Like this, concentration in something, recall of a memory,
and imagination are not conducted in only one center such as a
center of a visual sense, a center of an acoustic sense, and a
center of memory. Thinking from such a thing, it is important to
not only analyze each individual center separately but also
comprehensively study the whole cerebrum which controls them (FIG.
2).
[0022] Meanwhile, since around 1980 in Europe and USA, a concept
called Solution Focused Approach has been developed (FIG. 6).
[0023] This is a way of thinking that "it is important to treat an
affected part and, at the same time, maintain a healthy part
immediately."
[0024] This approach has been previously adopted mainly in
department of psychosomatic medicine although ambiguously, and is a
thinking way that, to treat the diseases that are not clearly
grasped when pursued by a 20-century diagnosing method with poor
laboratory data such as autonomic ataxia and physical abnormality,
it is important to recognize and make use of the intact functions
immediately rather than to detect and care the injured
functions.
[0025] In such a sense, this approach is going against the
scientific methodology involving mainly analysis, which is peculiar
to previous Westerner (Mr. Wilder Penfield (Canada) proposed an
analytical procedure, while Mr. Karl Lashley (Britain) proposed a
non-analytical holonic procedure).
[0026] Recently, a trend of adoption of the solution focusing
approach is prevailing also in a brain area to review the function
of cerebrum and brain anatomical cell structure.
[0027] This is the approach to improve functions by preventing
further expansion of a damaged part and maintaining an intact part,
a much larger region than the damaged part.
[0028] As such, it goes without saying that initial therapy is
important. However, there is a fact that, in most cases, initial
therapy, which is naturally conducted in other departments, is not
conducted in the department of psychiatry.
[0029] When "Solution Focusing Approach" is applied to cerebrum
study, it is considered more important to consider whole cerebrum
comprehensively rather than to center on a partial function center
of cerebrum as previously preferred. A whole is not necessarily a
sum of parts (holonic). It is thought that a whole is a whole, and
only when a balance is taken as a whole and safety is confirmed, a
higher order center of cerebrum works (FIG. 3).
[0030] A thinking way that a whole is more important than a part in
cerebrum study was derived as a result of detailed experiment in a
monkey in 1920's to 40's (Karl Lashley (Britain)).
[0031] At that time, the finding of more analytical method by
Wilder Penfield of Canada was a master stream among such ways of
thinking, and the Karl's method cannot be a master stream. However,
it was gradually spread worldwide, and in 1981, Roger Sperry
(1922-1994) who is a psychobiologist of USA received a Nobel Prize
for study of the function in left and right hemispheres of
cerebrum. The previous science technique to analyze more details
limit to studies showing that "a center of a visual sense is
present in 17.sup.th, 18.sup.th and 19.sup.th of lobus
occipitalis," and similar findings, and an idea such as the
function of a right/left brain and a whole brain has not come
out.
[0032] If the cerebrum function is greatly involved in a
psychiatric disease, and a disorder of the cerebrum function is
deeply involved therein, it is considered that a method to treat a
psychiatric disease becomes clearer by checking the cerebrum
function.
[0033] For example, focusing on senile dementia which is currently
increasing, a specific method will be discussed.
[0034] When any sign of dementia is suspected, the person first
admits to the hospital for examinations. This is a process that was
not present in the previous psychiatric hospital. In examinations,
a new system with standardized checking items, not depending on
subjective evaluation by a counselor is adopted, and the person's
condition is precisely grasped. Depending on a degree of
progression, a treating method is determined. Fundamentally, a
diseased part of cerebrum is suppressed and an intact part is
maintained by drug therapy to recover a decreased ability to the
original state.
[0035] The concept is very simple. When an affected part comes out,
it should be detected and suppressed as early as possible, and an
intact part should be maintained so that the person can live a rosy
later life. Of course, how to live depends on endeavor and device
of each person.
[0036] For a vivid independent later life, in view of medical
methodology, it is recommended that when any risk or sign of
dementia is pointed out, the person should admit to the hospital
for examinations to receive appropriate treatment as early as
possible.
[0037] As tuberculosis and Hansen's disease, which were previously
a refractory disease, became curable by initial therapy by a
physician who knows a whole, it is thought that such a time has
come when a psychiatric disease is also converted into
"evidence-based medicine" by introducing initial medicine mainly
including drug therapy focusing on the cerebrum function as its
basis (hospitalization for examinations.fwdarw.Solution Focused
Approach etc.) (FIG. 4).
[0038] There is no doubt that cerebrum is deeply involved in a
psychiatric disease, but in other physical diseases, the cerebrum
function can not be neglected. It has been known also from clinical
experience of the present inventor for more than 40 years that many
diseases improve further by treatment on cerebrum together with
local therapy.
[0039] It is thought that insulin therapy for diabetes and a
cholesterol-suppressing agent for obesity are all involved in
dysfunction of cerebrum, and it is natural to consider that
problems such as increased CRK and dementia arises in particular
occur more frequently from now on in a context with a brain.
[0040] Further, as shown in the present invention, it becomes
apparent that even a cancer can be cured by treating cerebrum. It
goes without saying that I, as a physician, hope more people to
know this finding.
[0041] As a conclusion, the present inventor thinks that,
regardless of the type of disease, the function of cerebrum
integrating mind and body must be paid more attention to treat the
disease. This is because, to say extremely, all information of a
body is inputted in a brain. In addition, psychological matters
including past, present, imagination and others are all together
inputted into cerebrum. Furthermore, natural phenomenon during the
years is memorized in a brain. Since cerebrum controls a body based
on the natural phenomenon recognizing that safety is assured, the
function of cerebrum has to be sufficiently maintained above
all.
[0042] In an elderly has concomitant diseases, it is necessary to
treat him/her by checking the peripheral part of a brain first. If
a weight is always put on a local site which is not so important,
this may conversely result in exacerbation of the state of the
whole body.
[0043] A whole and a part are both important. It is thought that
the scientific methodology in the 20.sup.th century focusing on a
part is changing to the scientific approach focusing on a whole and
further emphasizing relationship between a whole and a part in the
21.sup.st century.
[0044] It is thought that representative diseases addressed in such
a change are psychiatric disease and malignant tumor. On the other
hand, it is presumed that, as a theme in the medical field from now
on, elucidation of a gene will be greatly closed up without any
doubt.
[0045] With respect to "human genome plan" for which study and
development have been rapidly progressed since 1990's, that is, a
gene issue, in our country, only partial study of a DNA is
marginally getting going, and control of its whole is substantially
delayed. It is thought that application of gene technology in
treating diseases in this area must be vigorously conducted
starting from fundamental study.
[0046] Medicine to secure the healthy mind and body as early as
possible, focusing on the cerebrum. The present inventor thinks
that it is duty of a healthcare practitioner from now on to grasp
the condition precisely and improve the damaged ability by "new
medicine focusing on a whole body and maintaining a healthy part",
not by "modern medicine focusing on a part."
[0047] If a normal life becomes difficult, and a person begins to
suspect that he or she is ill, it is natural that he or she needs a
reliable physician who can cure it. Familial care is most
appreciate and only a family may be empathetic, but it goes without
saying that, in order to fundamentally solve a problem, a reliable
physician and reliable therapy are essential above all.
[0048] However, change in medical education, overfocus on
cultivation of physicians who can see only a part, and confusion
between medicine and welfare greatly destruct the clinical field of
medicine.
[0049] In 17.sup.th century, Descartes advanced the theory that
mind and body are separate. Since then, the Mind and Body Dualism
has been ever governed the medical field. However, medicine of
21.sup.st century must be changed in a way of putting importance on
a whole instead of a part. In other words, it is felt that a time
has come to think again what relation is present between a brain, a
body and a mind constituting a human.
[0050] Now, when this fundamental conversion is urged, attendance
of conational physicians and nurses is desired towards to
construction of "true medicine."
[0051] On the other hand, from accumulation of study of a brain and
treatment experience on a brain, it has been known that the
cerebrum function is greatly involved also in a cancer.
[0052] All information of a body is inputted in cerebrum. Cerebrum
also has the function of cognizing abnormality when present
anywhere. Cerebrum controls a whole body while maintaining safety
of a body.
[0053] When "onset of cancer", an abnormality of a body occurs,
cerebrum cognizes it and tries to exclude a cancer cell.
[0054] Then, one may have a question that "why a cancer develops in
human". The reason is that when the cognitive ability of cerebrum
is reduced by any reason, abnormality can not be found, permitting
proliferation of a cancer cell.
[0055] Therefore, it is concluded that, in order to basically
suppress a cancer, the cognizing ability of cerebrum should be
activated.
[0056] Studies up to date showed that a human normally uses only 3%
of cerebrum, and even when the cognitive ability is reduced, a
resting 97% intact part is maintained and the cognitive ability can
be enhanced again.
[0057] According to the present invention, in brief, when health of
a brain can be maintained, the risk of getting a cancer is
negligible. Moreover, the present inventor has explained many
actual cases where a cancer patient who received treatment of
cerebrum using a tranquilizer showed a recovery tendency.
[0058] Further, it has been known that even when a cancer has
entered a stage of proliferation/metastasis, intake of vitamin C
may suppress the proliferation. The cancer
cell-proliferation-preventing effect by vitamin C is also shown in
study of Dr. Linus Pauling who was rewarded a Novel prize.
[0059] The present inventor itself suffered from large intestine
cancer. After being discharged from hospital, the inventor has been
on a tranquilizer and vitamin C. In a health check thereafter,
proliferation and metastasis were not seen at all, and a cancer
specialist was surprised at it.
[0060] Additionally, when one suffers from a disease, only a family
is reliable. Although there is a term of regional medicine, one can
be taken care only by a family. However, a family can provide a
care but not treatment. Of course, one desires to find a reliable
physician who can really cure itself.
[0061] The present inventor itself is a physician who experienced a
major disease, and ardently felt the necessity of a reliable
physician who performs "evidence-based medicine" like the present
invention.
[0062] Dr. Greenfield describes a brain and a disease in Non-Patent
Literature 1 (Trends Biotechnol. 2005 January; 23(1):34-41).
However, the Literature does not describe and suggest treatment of
other diseases such as cancer utilizing the cognitive ability of a
brain.
[Non-Patent Literature 1]
[0063] Trends Biotechnol. 2005 January; 23(1): 34-41.
DISCLOSURE OF THE INVENTION
Problems to be Solved by the Invention
[0064] An object of the present invention is to develop a method of
enhancing the cognitive ability of a brain to fundamentally cure a
disease.
Means for Solving the Problems
[0065] The above object was attained by the present invention, in
which administration of vitamin C and a major tranquilizer
increased the cognitive ability of a brain, leading to cure of a
disease. Therefore, the present invention provides an
evidence-based therapy (FIG. 6).
[0066] Accordingly, the present invention provides the
following:
(1) A medicament for treating or preventing a disease, comprising a
combination of a major tranquilizer, and vitamin C or a salt
thereof. (2) The medicament according to item 1, wherein the major
tranquilizer is selected from the group consisting of a
butyrophenone derivative, a phenothiazine derivative and a
benzamide derivative. (3) The medicament according to item 1,
wherein the major tranquilizer is a butyrophenone derivative, and
the butyrophenone derivative is selected from the group consisting
of haloperidol, spiperone and timiperone. (4) The medicament
according to item 1, wherein the major tranquilizer is haloperidol.
(5) The medicament according to item 1, wherein the major
tranquilizer is administered at a half dose of treatment of a
psychiatric disease. (6) The medicament according to item 1,
wherein the major tranquilizer is administered at a daily dose of
0.25 mg to 1 mg in terms of haloperidol. (7) The medicament
according to item 1, wherein the vitamin C is ascorbic acid which
is an artificial substance. (8) The medicament according to item 1,
wherein the vitamin C is contained so that it is administered at a
daily dose of 600 mg to 1800 mg as an effective amount. (9) The
medicament according to item 1, further combined with drip
infusion. (10) The medicament according to item 1, wherein the drip
infusion is a physiological buffer containing maltose. (11) The
medicament according to item 1, wherein the drip infusion is an
Ardofed injection solution. (12) The medicament according to item
1, further combined with an antidepressant. (13) The medicament
according to item 10, wherein the antidepressant is administered
when blood potassium is decreased. (14) The medicament according to
item 10, wherein the antidepressant contains fluvoxamine maleate.
(15) The medicament according to item 10, wherein the
antidepressant is administered daily. (16) The medicament according
to item 1, further combined with an iron agent. (17) The medicament
according to item 12, wherein the iron agent comprises sodium
ferrous citrate. (18) The medicament according to item 9, wherein
the drip infusion is administered until appetite is worked up. (19)
The medicament according to item 1, wherein the major tranquilizer
is administered before bedtime. (20) The medicament according to
item 1, further combined with drip infusion and an antidepressant.
(21) The medicament according to item 1, further combined with drip
infusion and an iron agent. (22) The medicament according to item
1, further combined with drip infusion, an antidepressant and an
iron agent. (23) The medicament according to item 1, wherein the
vitamin C is further combined with pantothenic acid or a salt
thereof. (24) The medicament according to item 1, wherein the
disease includes at least one disease other than a psychiatric
disease. (25) The medicament according to item 1, wherein the
disease includes a disease selected from the group consisting of
cancer, muscular dystrophy and Huntington's chorea. (26) The
medicament according to item 10, wherein the cancer is selected
from large intestine cancer, colon cancer, rectum cancer, thyroid
cancer, esophagus cancer, chorionic cancer, gallbladder cancer,
neuroblastoma, maxillary cancer, oral cavity cancer, genitourinary
cancer, malignant lymphoma, liver cancer, prostate cancer, lung
cancer, lung cell cancer, breast cancer, stomach cancer, bladder
cancer, pancreas cancer, testis cancer, uterus cancer, corpus uteri
cancer, cervix uteri cancer, ovary cancer, pharynx cancer,
myelocytic leukemia, brain edema, biliary cancer, neuroblasto
tumor, melanocytoma, gastrinoma, insulinoma, carcinoid, kidney
cancer, testicle cancer, adult T cell leukemia, vagina cancer,
vulva cancer, skin cancer, upper airway cancer, head and neck
cancer, teratoma, gallbladder cancer, acute myelocytic leukemia,
acute lymphatic leukemia, malignant lymphoma, sarcoma, malignant
melanoma, lymphoma, lung squamous epithelium cancer and
spinocerebellar degeneration. (27) A method for treating or
preventing a disease, including a step of administering a major
tranquilizer, and vitamin C or a salt thereof to a subject
suffering from the disease. (28) The method according to item 27,
further including a step of giving drip infusion to the subject.
(29) The method according to item 27 or 28, further including a
step of administering an antidepressant to the subject when blood
potassium of the subject is reduced. (30) The method according to
any one of items 27 to 29, further including a step of
administering an iron agent to the subject when the subject has
anemia. (31) Use of a combination of a major tranquilizer, vitamin
C or a salt thereof in production of a medicament for treating or
preventing a disease. (32) The use according to item 31, wherein
the combination further comprises drops. (33) The use according to
item 31 or 32, wherein the combination further comprises an
antidepressant. (34) The use according to any one of items 31 to
33, wherein the combination further comprises an iron agent.
EFFECT OF THE INVENTION
[0067] The present invention exerts such an effect that almost any
diseases can be treated by a simple combination of two or more
kinds of drugs which have previously been used.
[0068] According to the present invention, since a patient can
receive therapy under a condition mild to the patient, the maximum
treatment effect can be exerted while exhaustion of a physical
strength of a patient is extremely suppressed, and an undesired
side effect can be avoided.
[0069] The aforementioned object, other objects, characteristics
and advantages of the present invention will become more apparent
from the following detailed explanation of embodiments of the
present invention with reference to the drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0070] FIG. 1 is a schematic view of a brain.
[0071] FIG. 2 is a schematic view in which structures of a brain
are classified.
[0072] FIG. 3 is a schematic view illustrating a process in which a
brain cognizes a disease.
[0073] FIG. 4 shows an example of disease therapy.
[0074] FIG. 5 is an illustration of evidence-based medicine.
[0075] FIG. 6 is an illustration of the Solution Focused
Approach.
BEST MODE FOR CARRYING OUT THE INVENTION
[0076] The present invention will be explained below. It is to be
understood that expression of a single form also includes a concept
of its plural form throughout the present specification, unless
otherwise indicated. Therefore, it is to be understood that an
article or an adverb in a single form (e.g. "a", "an", "the" and
the like) includes a concept of its plural form unless otherwise
indicated. In addition, it is to be understood that a word used in
the present specification is used in a sense normally used in the
art, unless otherwise indicated. Therefore, unless otherwise
defined, all the specialized terminology and scientific and
technical words used in the present specification have the same
meanings as those that are generally understood by a skilled person
in the art to which the present invention pertains. When
conflicted, the present specification (including definition) shall
control.
DEFINITION
[0077] The following is a list of definition of terms particularly
used in the present specification.
[0078] The "disease" which is a subject of the present invention
may be any disease, and it can usually be a disease or a disorder
which is associated with a disorder directly or indirectly
associated with the immune state or homeostasis of a body. Examples
of such a disease are not limited to, but include cancer, an
infectious disease with viruses or bacterium, allergy,
hypertension, hyperlipemia, diabetes, cardiac disease, brain
infarction, dementia, obesity, arteriosclerotic disease,
infertility, neuropsychiatric disease, cataract, progeria, and
ultraviolet radiation hypersensitivity.
[0079] The "disorder" which is a subject of the present invention
can be an arbitrary disorder associated with abnormality of a
body.
[0080] In one embodiment, the disease or disorder can be a
circulatory (blood cell or the like) disease or disorder. Examples
of such a disease or disorder are not limited to, but include
anemia (e.g. anaplastic anemia (particularly serious anaplastic
anemia), renal anemia, cancerous anemia, secondly anemia, or
refractory anemia), cancer or tumor (e.g. leukemia) and
hematopoietic failure after chemotherapy treatment thereof,
thrombocytopenia, acute myelocytic leukemia, (particularly, first
remission period (High-risk group), second remission period or
remission periods thereafter) acute lymphatic leukemia
(particularly, first remission period, second remission period or
remission periods thereafter), chronic myelocytic leukemia
(particularly, chronic period, transition period), malignant
lymphoma (particularly, first remission period (High-risk group),
second remission period or remission periods thereafter), and
multiple myeloma (particularly, early stage after sideration).
[0081] In another embodiment, the disease or disorder may be a
nervous disease or disorder. Examples of such a disease or disorder
are not limited to, but include dementia, stroke and sequela
thereof, brain tumor, and spinal damage.
[0082] In another embodiment, the disease or disorder may be an
immune disease or disorder. Examples of such a disease or disorder
are not limited to, but include the following: T cell deficiency,
and leukemia.
[0083] In another embodiment, examples of the disease or disorder
may be a motor or skeletal disease or disorder. Examples of such a
disease or disorder are not limited to, but include: bone fracture,
osteoporosis, arthral bone dislocation, subluxation, ligament
rupture, ligament damage, osteoarthritis, bone sarcoma, Ewing's
sarcoma, osteogenesis imperfecta, and osteochondrodysplasia.
[0084] In another embodiment, the disease or disorder may be a
dermal disease or disorder. Examples of such a disease or disorder
are not limited to, but include the following: atrichia, melanoma,
skin malignant lymphoma, angiosarcoma, histiocytosis, bullosis,
pustulosis, dermatitis, and eczema.
[0085] In another embodiment, the disease or disorder may be an
endocrine system disease or disorder. Examples of such a disease or
disorder are not limited to, but include
hypothalamus.cndot.pituitary gland disease, thyroid gland disease,
accessory thyroid gland (parathyroid gland) disease, renal cortex
medullae disease, saccharidoses, abnormal lipid metabolism,
abnormal protein metabolism, abnormal nucleic acid metabolism,
congenital abnormal metabolism (phenyl ketonuria, galactosemia,
homocystinuria, maple syrup urine disease), analbuminemia, ascorbic
acid synthesizing ability deficiency, hyperbilirubinemia,
hyperbilirubinuria, kallikrein deficiency, mast cell deficiency,
diabetes insipidus, vasopressin secretion abnormality, dwarfism,
Wolman's disease (acid lipase deficiency), and
mucopolysaccharidosis type VI.
[0086] In another embodiment, the disease or disorder can be a
respiratory disease or disorder. Examples of such a disease or
disorder are not limited to, but include the following: lung
disease (e.g. pneumonia or lung cancer), and bronchial disease.
[0087] In another embodiment, the disease or disorder can be an
alimentary system disease or disorder. Examples of such a disease
or disorder are not limited to, but include the following:
esophagus disease (e.g. esophagus cancer), stomach.cndot.duodenum
disease (e.g. stomach cancer or duodenum cancer), small
intestine.cndot.large intestine disease (e.g. large intestine
polyp, colon cancer or rectum cancer), biliary tract disease, liver
disease (e.g. cirrhosis hepatic, hepatitis (type A, type B, type C,
type D, type E or the like), fulminant hepatitis, chronic
hepatitis, primary liver cancer, alcoholic liver disorder or drug
liver disorder), pancreatic disease (acute pancreatitis, chronic
pancreatitis, pancreas cancer, cystic pancreas disease),
peritonea.cndot.abdominal wall.cndot.diaphragma disease (hernia or
the like), and Hirschsprung's disease.
[0088] In another embodiment, the disease or disorder can be a
urinary disease or disorder. Examples of such a disease or disorder
are not limited to, but include the following: kidney disease
(renal failure, primary glomus disease, renal vascular disorder,
convoluted tubule functional abnormality, interstitial renal
disease, renal disorder due to systemic disease or kidney cancer),
and bladder disease (inflammation of the bladder or bladder
cancer).
[0089] In another embodiment, the disease or disorder can be a
reproductive system disease or disorder. Examples of such a disease
or disorder are not limited to, but include the following: male
reproductive disease (male infertility, prostate hypertrophy,
prostate cancer or testis cancer), and female reproductive disease
(female infertility, ovary functional disorder, fibroid,
adenomyosis of the uterus, uterus cancer, endometriosis, ovary
cancer or villosity disease).
[0090] In another embodiment, the disease or disorder can be a
circulatory disease or disorder. Examples of such a disease or
disorder are not limited to, but include the following: heart
failure, angina cordis, myocardial infarction, arrhythmia, valvular
disease, cardiac muscle.cndot.capsula cordis disease, congenital
cardiac disease (e.g. defect of the interatrial septum,
interventricular septal defect, patent ductus arteriosus or
tetralogy of Fallot), arterial disease (e.g. arteriosclerosis or
aneurism), venous disease (e.g. varicosity), and lymph duct disease
(e.g. lymphatic edema).
[0091] Examples of the disease or disorder curable by an immune
system which can be treated or ameliorated by the present invention
are not limited to, but include atopic dermatitis, and chronic
arthritis rheumatoid.
[0092] Examples of the cancer which can be treated or ameliorated
by the present invention are not limited to, but include brain
tumor, leukemia, stomach cancer, lung cancer, liver cell cancer,
metastatic cancer, primary breast cancer, recurrent breast cancer,
primary liver cancer, biliary tract cancer, pancreas cancer, kidney
cancer, prostate cancer, testis cancer, uterine corpus cancer,
ovary cancer, lung small cell cancer, leukemia, biliary tract
cancer, digestive system cancer, large intestine cancer, liver
cancer, metastatic liver cancer, cervix uteri cancer, colon cancer,
rectum cancer, thyroid cancer, breast cancer, urinary cancer,
uterus cancer, esophagus cancer, cystic mole, chorionic cancer,
ectopic HCG producing tumor, cholecystis cancer, bile duct cancer,
neuroblastoma, maxillary cancer, oral cavity cancer, oral cavity
bottom cancer, genitourinary cancer, thyroid cancer, malignant
lymph (Hodgkin and non-Hodgkin), bladder cancer, hematopoietic
tumor, prostate cancer accompanying bone metastasis, last stage
cancer, neuroblast tumor, lung small cell cancer, lung non-small
cell cancer, melanocytoma, gastrinoma, insulinoma, carcinoid,
malignant tumor accompanying hypercalcemia, adult T cell leukemia,
vulva cancer, skin cancer, upper airway cancer, head and neck
cancer, teratoma, bladder cancer, .beta. cell leukemia, testis
tumor, digestive system cancer, acute myelocytic leukemia, acute
lymphatic leukemia, malignant tumor, primary liver cancer, sarcoma,
malignant melanoma, lymphoma, and lung squamous epithelium
cancer.
[0093] Examples of the infectious disease which can be treated or
ameliorated by the present invention are not limited to, but
include HBV infectious disease, HCV infectious disease, various
bacterial infectious diseases, fungal infectious disease, viral
infectious disease, HIV-1 infection, HIV-2 infection, herpesvirus
(including HSV-1, HSV-2, CMV, VZV, HHV-6, HHV-7, and EBV without
limitation) infection, adenovirus infection, poxvirus infection,
human papilloma virus infection, hepatitis virus (e.g. including
HAV, HBV, and HCV without limitation) infection, Helicobacter
pylori infection, parasitic organism infection, and HTLV-1
infection.
[0094] Examples of the lifestyle disease which can be treated or
ameliorated by the present invention are not limited to, but
include diabetes, arteriosclerosis (including brain infarction,
angina cordis, and myocardiac infarction without limitation),
hypertension, malignant tumor, emphysema, and regressive change of
bone.
[0095] Examples of the parasite disease which can be treated or
ameliorated by the present invention are not limited to, but
include amebiasis, babesiasis, coccidiosis, cryptospolidiosis,
dientamebiasis, dourine, external parasitic organism infectious
disease, giardiasis, helminthiasis, leishmaniasis, Schistosoma
infection, theileriasis, toxoplasmosis, trypanosomiasis, as well as
Trichomonas infection and sporozoan (e.g. Plasmodium virax,
Plasmodium falciparium, Plasmodium malariae, and Plasmodium ovale)
infection, scabies, Japanese river fever, eye infection, intestine
disease (e.g. bloody flux, giardiasis), liver disease, lung
disease, opportunistic infection disease (e.g. AIDS-associate), and
malaria.
[0096] Examples of the immune exacerbation which can be treated or
ameliorated by the present invention are not limited to, but
include allergic dermatitis and psoriasis.
[0097] Examples of the immunodeficiency which can be treated or
ameliorated by the present invention are not limited to, but
include pyoderma, oral candidiasis, and virus infectious
disease.
[0098] Examples of the drug poisoning which can be treated or
ameliorated by the present invention are not limited to, but
include alcoholic poisoning, nicotine poisoning, and heroin
poisoning.
[0099] The "lifestyle disease" in the present specification refers
to an arbitrary disease in which cause of a disease is gradually
spread through repetition of a way of daily life or bad habit, and
symptom comes out when the relevant person reaches a certain age.
Examples thereof include diabetes, hypertension, hyperlipemia, gout
(hyperuricemia), obesity, arteriosclerosis, brain infarction,
myocardiac infarction, pancreatitis, respiratory disease,
stomach.cndot.duodenum ulcer, hepatic function disorder,
osteoporosis, cancer, and periodontal disease, and the lifestyle
disease is a category according to a disease classifying method
which puts a weight on cause as compared with the aforementioned
sideration site. Since it is thought that in such a lifestyle
disease, symptom is exacerbated due to reduction in the cognitive
ability of a brain in any case, it is understood that the method of
the present invention can act on any of these diseases.
[0100] According to the present invention, in treatment of the
aforementioned diseases, any negative effect due to the previous
drug therapy was avoided. Enablement of curing of last stage cancer
which was not previously cured certainly can be said to be the
remarkable effect which was impossible or difficult in conventional
techniques.
[0101] In one embodiment, the present invention can be useful in
formulating an agent for preventing, ameliorating or treating
central disease (e.g. apoplexia cerebri, apoplexia cerebri
sequelae, delayed nerve cell death, Alzheimer's disease, dementia,
eating disorder, Parkinson's disease, multiple sclerosis, or
Creutzfeldt-Jakob disease), inflammatory disease (e.g. allergy,
asthma or rheumatoid), circulatory disease (e.g. ischemic disorder,
reperfusion disorder, hypertension, heart hypertrophy, angina
cordis or arteriosclerosis), cancer (e.g. non-small cell lung
cancer, ovary cancer, prostate cancer, stomach cancer, bladder
cancer, breast cancer, cervix uteri cancer, colon cancer or rectum
cancer), metabolism disease (e.g. diabetes, diabetic complication,
obesity, arteriosclerosis, gout, cataract, hepatitis, amyloidosis
or Wilson's disease), immune disease (e.g. autoimmune disease),
digestive organ disease (e.g. stress ulcer, acute pancreatitis,
inflammatory bowl disease, ulcerous colitis, stomach ulcer,
duodenum ulcer, gastric inflammation or reflux esophagitis),
autoimmune disease (chronic arthritis rheumatoid, multiple
sclerosis or systemic erythematodes), degenerative disease
(amyloidosis, hemosiderosis or Wilson's disease), ischemic nerve
cell damage (apoplexia cerebri, apoplexia cerebri sequelae or
delayed nerve cell death), ischemic.cndot.reperfusion damage,
cystic fibrosis, malignant tumor, infectious disease (multi organ
failure due to sepsis or acute respiratory distress syndrome),
liver failure, kidney failure, drug poisoning, heavy metal
poisoning, radiation damage, ultraviolet damage (damage of skin, or
lens or retina of eye due to ultraviolet-ray), other living body
invasion (damage of skin or tissue due to heat or acid), viral
disease (type B hepatitis, type C hepatitis, type D hepatitis, type
E hepatitis, acquired immunodeficiency syndrome or adult leukemia)
or aging.
[0102] In the present specification, it has been known that, at
least actually, type B hepatitis, type C hepatitis, acquired
immunodeficiency syndrome (AIDS), diabetes, diabetic complication,
prostate hypertrophy, gout, hepatitis, autoimmune disease,
malignant lymphoma, pancreas cancer, cervix uteri cancer, oral
cavity bottom cancer, kidney cancer, hypertension, ulcerous
colitis, chronic arthritis rheumatoid, chronic granulomatosis,
inflammatory bowl disease, neutropenia and neutrophilia, as well as
other disease, for example, substantially arbitrary cancer, viral
disease, metabolism disease, circulatory disease, digestive organ
disease, inflammatory disease, central disease, immune disease,
infectious disease and lifestyle disease seem to be cured.
[0103] In the present invention, by increasing the disease
cognitive ability of a brain, it was revealed that an arbitrary
disease can be cured. In principle, since a brain can cognize any
disease, it is to be understood that the present invention is
effective for an arbitrary disease.
[0104] In the present specification, "intravital" or "in vivo"
refers to the inside of a living body. In a particular context,
"intravital" refers to a position at which an objective tissue or
organ is to be disposed.
[0105] In the present specification, the "subject" refers to an
organism to which treatment of the present invention is applied,
and is also called a "patient". The patient or the subject can be
preferably a human.
[0106] In another embodiment, in the present invention, it is
planned that a drug (e.g. anticancer agent) is used together. Such
a drug can be an arbitrary drug known in the art and, for example,
such a drug can be an arbitrary drug (e.g. anti-cancer agent or
antibiotic) known in pharmacy. Naturally, such a drug can be two or
more kinds of other drugs. Preferably, the drug can be administered
at the same time with or at a different time from thermotherapy.
Examples of such a drug include drugs listed in Japanese
Pharmacopoeia latest edition, US Pharmacopeia latest edition, or
latest edition of Pharmacopoeia in other countries.
[0107] In the present specification, the "major tranquilizer" is
one of psycholeptics (generic name of a drug which suppressively
acts on psychiatric function or emotion, and gives little change to
other central nervous function) and, among them, refers to a drug
by which anxiety or tension is relieved, and conscious disorder or
sleeping does not occur at a normal dose. (On the other hand, a
minor tranquilizer is used for the purpose of treating sleeping
induction or anti-epilepsia, in addition to treating anxiety,
agrypnia, or nervous disease with a drug). This is also called
neuroplegica or antipsychotic drug. Reserpine (component of Indian
snakeroot), chlorpromazine, haloperidol, and lithium carbonate
belong to this. Examples of the major tranquillizer which is
representatively used include a butyrophenone derivative (e.g.
haloperidol, spiperone or timiperone), a phenothiazine derivative
(fluphenazine maleate, trifluoperazine maleate, perphenazine, or
prochlorperazine), a benzamide derivative (nemonapride or the like)
an atypical antipsychotic drug (risperidone or the like) and the
like.
[0108] In the present specification, an "amount" or a "dose" for
the "psychiatric disease treatment" can be set based on
Pharmacopoeia or a minimum amount which is normally used. For
haloperidol, at an initial stage, an amount is started with 0.75 to
2.25 mg a day, and gradually increased, and since a maintenance
amount is 3 to 6 mg a day, and a maximum amount per day is 40 mg,
0.75 mg is adopted as a standard amount. For spiperone, in the
first week, an amount is started with 0.45 to 1.5 mg, and since 1.5
to 4.5 mg a day is used thereafter, 0.45 mg is adopted as a
standard amount. For timiperone, at an initial stage, an amount is
started with 0.5 to 3 mg a day, and since an amount is gradually
increased to 3 to 12 mg a day thereafter, 0.5 mg is adopted as a
standard amount.
[0109] In the present specification, the "vitamin C" (ascorbic
acid, cevitamic acid, hexuronic acid) is a colorless crystalline
substance (C.sub.6H.sub.8O.sub.6, molecular weight 176.13), a
melting point is 190 to 192.degree. C., and an L body of ascorbic
acid is vitamin C. Specific rotation degree=+23.degree. (c=1, in
water). It is soluble in water and insoluble in ethanol. It is a
substance which is weak to heat, and has a strong reducing force
and an ultraviolet absorption maximum of 265 nm (aqueous solution).
It has an oxidation reduction potential of +0.058 V (pH 7.0). Its
natural body is contained in fresh fruit juice, green tea, radish,
or green leaf at a large amount, and has the anti-scorbutus
activity. A D body does not have that efficacy. It exhibits acidity
in an aqueous solution because one of enol-form hydroxy groups is
dissociated, and it makes a water-soluble neutral monoalkali salt.
It is thought that it is involved in an oxidation reduction system,
and exhibits the activity as a vitamin in a living body. It is
present in adrenal gland at a particularly large amount in an
animal body, and is contained also in the liver, pituitary gland,
corpus luteum, and thymus at a large amount. It easily undergoes
reversible oxidation by various oxidizing agents, free oxygen (in
the presence of copper) or polyphenol oxidizing enzyme,
specifically, ascorbic acid oxidizing enzyme, and converted into
dehydroascorbic acid, thereby, they become an electron donor and an
electron receptor, respectively. Thus, it is presumed that it plays
a role of biological oxidation reduction as a hydrogen transporter.
Ascorbic acid functions in hydroxylation of proline and lysine in
collagen biosynthesis, metabolism of tyrosine and biosynthesis of
catecholamine, detoxication of a living body foreign matter,
suppression of production of nitrosoamine, hydroxylation of
cholesterol into 7.alpha.-cholesterol, absorption of iron,
reduction of cytochrome c, activation of NADH reductase, metabolism
of copper, and immune activation. Ascorbic acid deficiency (vitamin
deficiency) is mainly involved in deficiency of collagen
biosynthesis, and is characterized in bleeding tendency such as
scorbutus. It appears in a human, a monkey and a guinea pig lacking
.alpha.-gulono-.gamma.-lactone oxidase for ascorbic acid synthesis,
but a necessary amount is sufficiently synthesized in a body of a
rat, a dog and a rabbit. In its synthesis route,
L-gulono-.gamma.-lactone is produced from D-glucose via
L-glucuronic acid and L-gulonic acid and, further,
L-gulono-.gamma.-lactone oxidase acts thereon to produce ascorbic
acid. Primate including a human, an elephant, a guinea pig, a
certain bird, a bat, and fish is genetically deficient in
L-guluno-.gamma.-lactone oxidase which catalyzes a final stage, and
can not bio-synthesize ascorbic acid. Ascorbic acid is required at
a largest amount among vitamins, a necessary amount a day for an
adult is about 50 mg, and a minimum necessary amount is 6.5 mg. For
quantitation, a method of utilizing reduction of an indophenol dye,
2,4-dichlorophenol indophenol is most frequently used. In the
present invention, it is preferable to administer an artifact of
vitamin C.
[0110] In the present invention, the "drip infusion" refers to drip
infusion of a physiological buffer with or without specified
components. As used in the present specification, any substance may
be used as the drip infusion as far as it is a physiological buffer
which prevents elevation of a body temperature. Representative
examples include a physiological buffer containing maltose.
[0111] In the present specification, the "physiological buffer"
refers to an arbitrary buffer which can be physiologically adapted.
Examples of such a physiological buffer include a physiological
saline (sodium chloride solution prepared so as to be isotonic with
a body fluid component (particularly, serum), normally 0.9% NaCl:
also called normal saline (a name of US Pharmacopoeia regarding a
sodium chloride sterile aqueous solution isotonic with a body
fluid)), a physiological salt solution (a mixed solution of salts
used as a medium solution which makes isolated organs or tissues
retain the normal function over a long term; a cation component of
a solution is mainly Na.sup.+, and K.sup.+, Ca.sup.2+ and Mg.sup.2+
are added thereto and, further, a buffer such as sodium bicarbonate
NaHCO.sub.3 and sodium dihydrogen phosphate NaH.sub.2PO.sub.4 are
added to adjust a pH; glucose as an energy source is added in some
cases), a Japanese Pharmacopoeia physiological saline, a Japanese
Pharmacopoeia glucose injection solution, a 10% maltose injection
solution, a Ringer's solution, a Lock's solution and a Tyrode's
solution. Specifically, an Aldofed injection solution can be
adopted.
[0112] In the present specification, the "antidepressant drug" or
the "antidepressive drug" refers to a medicament which relieves
oppression by enhancing the central activity of sympathetic nerve.
Examples thereof include imipramine and tranylcypromine. In the
present specification, when blood potassium is decreased, it is
administered. Specifically, it is preferable that fluvoxamine
maleate is administered.
[0113] In the present specification, the "iron agent" is a drug
containing iron as an ingredient, and serves for the purpose of
increasing blood. Examples thereof include iron lactate, an iron
iodide syrup, iron citrate, and iron sulfate. Preferably, sodium
ferrous citrate is used, being not limiting.
(Administration.cndot.infusion.cndot.medicament)
[0114] A medicament prepared with the factor of the present
invention can be provided in an arbitrary preparation form as far
as it is a form suitable for introduction into an organism.
Examples of such a preparation form include solutions, injectables,
and sustained release agents. Examples of an administration method
include oral administration, parenteral administration (e.g.
intravenous administration, intramuscular administration,
subcutaneous administration, intradermal administration, mucosal
administration, rectal administration, vaginal administration,
local administration to an affected part, or dermal
administration), and direct administration to an affected part. A
form of delivery to a brain is preferable. Formulations for such
administration can be provided in an arbitrary preparation form.
Examples of such a preparation form include solutions, injectables,
and sustained release agents. The composition and the medicament of
the present invention, when administered systemically, can be a
form of an aqueous solution which does not contain pyrogen, and can
be received orally. Preparation of such a pharmaceutically
acceptable protein solution is within the technical range of a
person skilled in the art, provided that considerable attention is
paid to pH, isotonicity and safety.
[0115] Injectables can be prepared by the method which is
well-known in the art. For example, after being dissolved in a
suitable solvent (physiological saline, buffer such as PBS or
sterilized water), injectables can be prepared by filtration
sterilization with a filter and, then filling in a sterilized
container (e.g. ampoule or the like). The injectables may contain a
conventional pharmaceutical carrier if necessary. A non-invasive
administration method using a catheter can also be used.
[0116] In one embodiment, the medicament of the present invention
can be provided in a sustained release form. A dosage form in the
sustained release form can be any form known in the art as far as
it can be used in the present invention. Such a form can be, for
example, a rod-like (pellet-like, cylinder-like, or needle-like)
form, a tablet form, a disk-like form, a spherical form, or a
sheet-like form. A method of preparing the sustained-release form
is known in the art, and is described, for example, in Japanese
Pharmacopoeia, US Pharmacopoeia, and Pharmacopoeia in other
countries, and examples of the method of preparing the
sustained-release agent (sustaining administration agent) include a
method utilizing dissociation of a drug from a complex, a method of
preparing an aqueous suspension injection solution, a method of
preparing an oily injection solution or an oily suspension
injection solution, and a method of preparing an emulsion injection
solution (o/w-type or w/o-type emulsion injection solution).
[0117] The composition or the kit of the present invention can also
contain a material compatible with a living body. This material
compatible with a living body can contain at least one member
selected from the group consisting of silicone, collagen, gelatin,
a copolymer of glycolic acid and lactic acid, an ethylene-vinyl
acetate copolymer, polyurethane, polyethylene,
polytetrafluoroethylene, polypropylene, polyacrylate and
polymethacrylate. Silicone is preferable because of easy molding.
Examples of the biodegradable polymer include collagen, gelatin, a
polymer or a copolymer synthesized by catalyst-free dehydration
polycondensation from one or more kinds of members selected from
the group consisting of .alpha.-hydroxycarboxylic acids (e.g.
glycolic acid, lactic acid, and hydroxybutyric acid),
hydroxydicarboxylic acids (e.g. malic acid) and
hydroxytricarboxylic acids (e.g. citric acid), or a mixture
thereof, poly-.alpha.-cyanoacrylic acid ester, polyamino acid (e.g.
poly-.gamma.-benzyl-L-glutamic acid), and polyacid anhydride such
as a maleic anhydride-based copolymer (e.g. styrene-maleic acid
copolymer). A form of polymerization may be any of random, block
and graft and, when .alpha.-hydroxycarboxylic acids,
hydroxydicarboxylic acids, or hydroxytricarboxylic acids have an
optically-active centre in a molecule, any of a D-body, an L-body,
and a DL-body can be used. Preferably, a copolymer of glycolic
acid.cndot.lactic acid can be used.
[0118] In the present specification, the "instruction" describes
explanation of a method of administering the medicament of the
present invention to a person who performs administration such as a
physician, or a patient. This instruction describes statement of
instructing administration of the medicament of the present
invention. In addition, statement of instructing administration
(e.g. via injection) to a skeletal muscle as an administration site
may be described in the instruction. This instruction is produced
according to a format prescribed by a regulatory agency (e.g.
Ministry of Health, Labor and Welfare in Japan, or Food and Drug
Administration (FDA) in USA) in a country where the present
invention is implemented, and there is described to the effect that
the instruction was approved by the regulatory agency. The
instruction is a so-called package insert and is usually provided
by a paper medium, being not limiting. For example, the instruction
can be provided by a form of an electronic medium (e.g. homepage
provided on the Internet or electronic mail). The frequency at
which the composition of the present invention is given to a
subject can be easily determined by a person skilled in the art, in
view of the use object, and the age, size, sex, medical history,
and a treatment process of a subject. Examples of the frequency
include administration once to several times a day, and daily to
once per several months (e.g. once a week to once a month). It is
preferable that administration once a week to once a month is
performed while following-up the course.
[0119] An amount of the composition, the compound or the medicament
used in the method of the present invention can be easily
determined by a person skilled in the art, in view of the use
object, and the age, size, sex and medical history of a subject, a
form or a kind of a polypeptide, a nucleic acid, a composition, a
medicament, and a form or a kind of a cell.
[0120] In the present specification, the "subject" refers to an
organism to which treatment of the present invention is applied,
and also to a "patient". The patient or the subject can be
preferably a human.
[0121] A solvent used for formulation of a medicament in the
present invention can have either of an aqueous or non-aqueous
nature. Further, its vehicle can contain other formulation
materials for altering or maintaining a pH, osmolarity, viscosity,
cleanness, color, sterilizing property, stability, isotonicity,
disintegrating rate, or odor. Similarly, the composition of the
present invention can contain other formulation materials for
altering or maintaining a release rate of an active ingredient, or
promoting absorption or permeation of an active ingredient.
[0122] The present invention, when formulated as a medicament or a
pharmaceutical composition, can be prepared for storage in a form
of a lyophilized cake or an aqueous solution, by mixing, if
necessary, a physiologically acceptable carrier, an excipient or a
stabilizer ((Remington's Pharmaceutical Sciences, 18th Edition, A.
R. Gennaro, ed., Mack Publishing Company, 1990), and a selected
composition having a purity to a desired degree.
[0123] Examples of such a pharmaceutically acceptable factor are
not limited to, but include: an antioxidant, a preservative, a
coloring material, a flavor material, a diluent, an emulsifier, a
suspending agent, a solvent, a filler, a bulking agent, a buffer, a
delivery vehicle, a diluent, an excipient and/or an agricultural or
pharmaceutical adjuvant. Representatively, in the medicament of the
present invention, an active ingredient (e.g. polypeptide or
nucleic acid) of the present invention can be administered in a
form of a composition together with one or more physiologically
acceptable carriers, excipients, or diluents. For example, the
suitable vehicle can be water for injection, a physiological
solution, or an artificial brain spinal liquid, and other
substances which are general to a composition for parenteral
administration can be supplemented to them. Such acceptable
carriers, excipients or stabilizers are non-toxic to a recipient,
and preferably inert at an administration amount and a
concentration used, and examples thereof include the following:
phosphate, citrate, other organic acids; antioxidant (e.g. ascorbic
acid); low molecular weight polypeptide; protein (e.g. serum
albumin, gelatin, or immunoglobulin); hydrophilic polymer (e.g.
polyvinylpyrrolidone); amino acid (e.g. glycine, glutamine,
asparagine, arginine or lysine); monosaccharide, disaccharide and
other carbohydrates (including glucose, mannose, maltose or
dextrin); chelating agent (e.g. EDTA); sugar alcohol (e.g. mannitol
or sorbitol); salt forming counterion (e.g. sodium); and/or
nonionic surface active agent (e.g. Tween, pluronic or polyethylene
glycol (PEG)).
[0124] The injectable can be prepared by a method well-known in the
art. For example, the injectable can be prepared by dissolving an
ingredient in a suitable solvent (physiological saline, buffer such
as PBS, or sterilized water), filtration-sterilizing this with a
filter and, then, filling this into a sterile container (e.g.
ampoule). This injectable may contain a conventional pharmaceutical
carrier, if necessary. An administration method using a
non-invasive catheter can also be used. Examples of the suitable
carrier include a neutral buffered physiological saline, and a
physiological saline mixed with serum albumin. Preferably, the
medicament of the present invention can be formulated as a
lyophilized agent using a suitable excipient (e.g. sucrose). Other
standard carriers, diluents and excipients can be contained, if
necessary. Other illustrated composition contains a Tris buffer at
a pH of 7.0 to 8.5, or an acetate buffer at a pH of 4.0 to 5.5, and
these can further contain sorbitol or a suitable substitute
therefor. A pH of the solution should be selected based on the
relative solubility of an active ingredient of the present
invention, at various pHs.
[0125] A procedure of formulating the preparation of the present
invention is known in the art, and is described, for example, in
Japanese Pharmacopoeia, US Pharmacopoeia, or Pharmacopoeia in other
countries. Therefore, as far as there is the description of the
present specification, a person skilled in the art can determine an
amount or frequency of a medicament to be administered, without
undue experiment.
[0126] In another embodiment, in the present invention, it is
planned to further administer other drugs. Such a drug can be an
arbitrary drug known in the art and, for example, such a drug can
be an arbitrary drug known in pharmacy (e.g. antibiotic).
Naturally, such a drug can be two or more kinds of other drugs.
Examples of such a drug include drugs listed, for example, in
Japanese Pharmacopoeia latest edition, US Pharmacopoeia latest
edition, or latest edition of Pharmacopoeia in other countries.
[0127] A disease which is a subject of the present invention is
cancer. In the present specification, the "cancer" refers to a
general malignant tumor.
[0128] In the present specification, the "solid cancer" refers to
cancer having a solid shape, and is a concept contrary to
hematopoietic tumor such as leukemia. Examples of such solid cancer
are not limited to, but include breast cancer, liver cancer,
stomach cancer, lung cancer, head and neck cancer, cervix uteri
cancer, prostate cancer, retinoblastoma, malignant lymphoma,
esophagus cancer, brain tumor, and bone tumor.
PREFERABLE EMBODIMENTS
[0129] A preferable embodiment of the present invention will be
explained below. An embodiment provided below is provided for
better understanding of the present invention, and it is understood
that the scope of the present invention is not limited by the
following description. Therefore, it is apparent that a person
skilled in the art can appropriately conduct alteration within a
range of the present invention in view of the description of the
present specification.
[0130] Although it is arbitrary, a basis of treatment of the
present invention can be performed roughly at two stages. (1) If
necessary, a body is cooled by drip infusion and, if necessary, two
kinds of antibiotics are given. (2) If necessary, by cooling a
brain by drip infusion, safety of a healthy part, which is 97% of a
brain, can be maintained. Since a brain is altered in nature at
38.5.degree. C. or higher, this is prevented to certainly leave a
healthy part. If a brain can be cooled, a procedure other than drip
infusion can be used. In addition, 60 to 80 thousand brain cells
are dying a day. In addition, there can be bacterial infection in a
urinary tract or lung of a patient. Then, in order to clean these
dead cells, if necessary, the function of macrophage (phagocytizing
cell), leukocyte or lymphocyte can be also enhanced using an
antibiotic. Macrophage and the like take a bacterium and a foreign
matter into a cell, digest them, and are greatly involved in
restoration of inflammation or immune action. (2) Parallel with
this, a combination of vitamin C and a major tranquilizer (strong
tranquilizer) of the present invention is ingested. Vitamin C is
ingested usually at 3 grams (capacity: 600 mg) in a tablet, or
normally at 9 grams (capacity: 1800 mg) which is well enough.
Vitamin C used in treatment in a preferable embodiment is slightly
different from natural vitamin C in a structure, because this is
far more effective. In addition, there is no problem that if
vitamin C is ingested with any drug or food. This has been found
out by a long-term clinical experience. In the present invention,
it was discovered that, by this combination, an ability of
cognizing which part of one's body is ill can be enhanced by a
brain. It has been found out that, by maintaining a healthy part
early, and enhancing the cognitive ability of a brain like this,
almost all diseases (e.g. cancer and psychiatric disease) are
directed to restoration. Also in senile dementia, an effective
therapy due to evidence-based medicine was attained by ingesting a
combination of drip infusion and an antibiotic, if necessary, which
is a basis of therapy cure by early therapy, as well as a
combination of vitamin C and a major tranquilizer of the present
invention.
[0131] In one aspect, the present invention provides a medicament
for treating or preventing a disease, including a combination of a
major tranquilizer, and vitamin C or a salt thereof.
[0132] In another aspect, the present invention provides a method
for treating or preventing a disease, including a step of
administering a major tranquilizer, and vitamin C or a salt thereof
to a subject suffering from the disease.
[0133] In one embodiment, the major tranquilizer used in the
medicament of the present invention can be a butyrophenone
derivative, a phenothiazine derivative, or a benzamide
derivative.
[0134] In another embodiment, the butyrophenone derivative used in
the present invention as a major tranquilizer can be haloperidol,
spiperone or timiperone, preferably haloperidol.
[0135] In one embodiment, the major tranquilizer to be administered
is preferably administered at an amount which is half dose of an
amount of psychiatric disease treatment, being not limiting.
[0136] In another embodiment, a dose of a major tranquilizer
administered in the present invention can be a daily dose of 0.25
mg to 1 mg in terms of haloperidol. It has been found out in the
present invention that, by using a dose smaller than an amount used
in a psychiatric disease, the cognitive ability of a brain can be
enhanced.
[0137] Preferably, the major tranquilizer is administered before
bedtime, being not limiting.
[0138] Vitamin C used in the present invention can be ascorbic acid
which is an artifact. This is because it has been empirically found
out that the artifact is a several-fold to a several thousands-fold
better in the effect than vitamin C which is a natural
substance.
[0139] In one embodiment of the present invention, in the
medicament of the present invention, vitamin C is contained so that
a daily dose of 600 mg to 1800 mg as an effective amount is
administered, being not limiting.
[0140] In one embodiment, vitamin C may be further combined with
pantothenic acid or a salt thereof, and this is not necessarily
essential.
[0141] In the combinatorial therapy of the present invention, it is
preferable to further combine drip infusion. Without desiring to be
bound by a theory, it was found out in the present invention that
it is optimal for cognizing a disease of a brain to maintain a
body, particularly a brain, at a low temperature. Therefore, it is
to be understood that, as a solution used in drip infusion, any
solution may be used as far as a body, particularly, a brain can be
maintained at a low temperature. In a preferable embodiment, a
physiological buffer supplying energy is preferable. For supplying
energy, glucose or maltose can be utilized. Maltose is preferable.
This is because maltose can supply energy which is about 2-fold
energy of glucose at the same osmotic pressure. It is to be
understood that, as the physiological buffer, any buffer can be
used as far as it is physiologically compatible. Examples of the
physiological buffer containing maltose include an Aldofed
injection solution. In an embodiment, this drip infusion is
administered until appetite is worked up.
[0142] In another embodiment, the medicament of the present
invention can be characterized in that an antidepressant is
combined. The antidepressant can be administered when blood
potassium is decreased. Examples of such an antidepressant include
fluvoxamine maleate. The antidepressant to be administered in the
present invention is preferably administered daily, or may be
administered arbitrarily.
[0143] In another embodiment, the medicament of the present
invention can be characterized in that an iron agent is combined.
In a preferable embodiment, the iron agent can include sodium
ferrous citrate, but other iron agents may also be used.
[0144] In a preferable embodiment of the present invention, the
combinatorial medicament of the present invention may be a
combination of drip infusion and an anti-depressant, in addition to
a combination of the major tranquilizer and vitamin C. In this
case, the aforementioned arbitrary preferable effect is
exerted.
[0145] In a preferable embodiment of the present invention, a
combinatorial medicament of the present invention may be further
combined with drip infusion and an iron agent, in addition to a
combination of the major tranquilizer and vitamin C. Also in this
case, the arbitrary preferable effect described above in the
present specification is exerted.
[0146] In a preferable embodiment of the present invention, a
combinatorial medicament of the present invention may be further
combined with drip infusion, an antidepressant and an iron agent,
in addition to a combination of the major tranquilizer and vitamin
C. Also in this case, the arbitrary preferable effect described
above in the present specification is exerted.
[0147] The disease which is a subject of the present invention can
be an arbitrary disease and, particularly, is remarkably
characterized in that at least one disease (e.g. cancer, muscular
dystrophy and Huntington's chorea) is included. The cancer which is
a subject of the present invention can be large intestine cancer,
colon cancer, rectum cancer, thyroid gland cancer, esophagus
cancer, chorionic cancer, gallbladder cancer, neuroblastoma,
maxillary cancer, oral cavity cancer, genitourinary cancer,
malignant lymphoma, liver cancer, prostate cancer, lung cancer,
lung cell cancer, breast cancer, stomach cancer, bladder cancer,
pancreas cancer, testicle cancer, uterus cancer, uterine corpus
cancer, cervix uteri cancer, ovary cancer, pharyngeal cancer,
myelocystic leukemia, brain tumor, biliary tract cancer, neuroblast
tumor, melanocytoma, gastrinoma, insulinoma, carcinoid, kidney
cancer, testis cancer, adult T cell leukemia, vagina cancer, vulva
cancer, skin cancer, upper airway cancer, head and neck cancer,
teratoid, gallbladder cancer, acute myelocystic leukemia, acute
lymphatic leukemia, malignant lymphoma, sarcoma, malignant
melanoma, lymphoma, lung squamous epithelium cancer and
spinocerebellar degeneration.
[0148] In another embodiment, a psychiatric disease such as
dementia can be a subject. The remarkable effect of the present
invention should be recognized in that, even at a dose which was
not previously thought to be a treatment dose, a surprising curing
effect can be exerted by joint use of vitamin C.
[0149] Reference literatures such as scientific literatures,
patents, and patent applications cited in the present specification
are incorporated by reference in their entirety in the present
specification to such an extent that they are specifically
described, respectively.
[0150] The present invention has been explained above by showing a
preferable embodiment for easy understanding. The present invention
will be explained below based on examples, but the aforementioned
explanation and the following examples are provided only for the
purpose of illustration, and are not provided to limit the present
invention. Therefore, the scope of the present invention is not
limited to the embodiments and examples which are specifically
described in the present specification, and is limited only by
claims.
EXAMPLES
[0151] The present invention will be explained in more detail below
by way of examples, but this invention is not limited by the
following examples at all. As for reagents used in the following
examples, those commercially available from medicament
manufacturers were used with some exceptions. A clinical trial was
performed according to a standard given by the government after an
informed consent was obtained from a patient as a subject.
[0152] (Cancer Marker to be Used)
[0153] In the present examples, the following cancer markers (tumor
markers) were used or can be used, if necessary.
TABLE-US-00001 List of tumor marker normal value Marker name Normal
value Main diseases as a subject ACT 21-38 mg/dl brain tumor
.cndot. leukemia .cndot. stomach cancer .cndot. lung cancer AFP 10
ng/ml or liver cell cancer .cndot. metastatic less liver cancer
BCA225 160 U/ml or primary breast cancer .cndot. recurrent less
breast cancer BFP 75 ng/ml or primary liver cancer .cndot. biliary
less tract cancer .cndot. pancreas cancer .cndot. kidney cancer
.cndot. prostate cancer .cndot. testis cancer .cndot. corpus uteri
cancer .cndot. ovary cancer .cndot. lung cell cancer .cndot.
leukemia CA15-3 30 U/ml or primary breast cancer .cndot. recurrent
less breast cancer CA19-9 37 U/ml or pancreas cancer .cndot.
biliary tract less cancer .cndot. digestive system cancer .cndot.
ovary cancer .cndot. corpus uteri cancer .cndot. lung cancer CA50
35 U/ml or liver cancer .cndot. biliary tract less cancer .cndot.
digestive system cancer .cndot. ovary cancer .cndot. corpus uteri
cancer .cndot. lung cancer CA72-4 4.0 U/ml or stomach cancer
.cndot. large intestine less cancer .cndot. ovary cancer .cndot.
pancreas cancer .cndot. lung cancer .cndot. liver cancer .cndot.
biliary tract cancer .cndot. breast cancer CA125 35 U/ml or ovary
cancer .cndot. liver cancer less biliary tract cancer .cndot.
pancreas cancer CA130 35 U/ml or ovary cancer .cndot. cervix uteri
less cancer .cndot. lung cancer .cndot. liver cell cancer .cndot.
pancreas cancer .cndot. biliary tract cancer .cndot. corpus uteri
cancer .cndot. stomach cancer .cndot. large intestine cancer CA602
63 U/ml or same line as CA130/CA125 less CEA 5.0 ng/ml or colon
cancer .cndot. rectum cancer .cndot. less pancreas cancer .cndot.
biliary tract cancer .cndot. lung cancer .cndot. stomach cancer
.cndot. thyroid gland cancer .cndot. breast cancer .cndot. urologic
cancer .cndot. uterine cancer .cndot. liver cell cancer .cndot.
esophagus cancer .cndot. ovary cancer DUPAN-2 400 U/ml or pancreas
cancer .cndot. biliary tract less cancer .cndot. liver cell cancer
.cndot. esophagus cancer .cndot. stomach cancer .cndot. large
intestine cancer HCG-.beta. 0.2 mg/ml or cystic mole .cndot.
chorionic cancer .cndot. less ectopic HCG-producing tumor IAP 500
m/ml or gallbladder cancer .cndot. less neuroblastoma .cndot.
leukemia .cndot. maxillary cancer .cndot. esophagus cancer .cndot.
pancreas cancer .cndot. ovary cancer .cndot. kidney cancer .cndot.
lung cancer .cndot. biliary tract cancer .cndot. oral cavity cancer
.cndot. genitourinary cancer .cndot. large intestine cancer .cndot.
thyroid gland cancer .cndot. malignant lymphoma .cndot. stomach
cancer .cndot. bladder cancer .cndot. testis cancer .cndot.
prostate cancer .cndot. cervix uteri cancer .cndot. liver cancer
.cndot. breast cancer ICDH 3-10 U/l liver cancer .cndot. metastatic
liver cancer KMO-1 5300 U/ml or pancreas cancer .cndot. gallbladder
less cancer .cndot. biliary tract cancer .cndot. liver cancer
.cndot. stomach cancer .cndot. large intestine cancer .cndot. ovary
cancer .cndot. (less than 8-fold) lung cancer .alpha.Marogloblin
120-320 mg/dl hematopoietic tumor .cndot. prostate cancer
accompanying bone metastasis .cndot. last stage cancer NCC-ST-439
7.0/ml or pancreas cancer .cndot. biliary tract less cancer .cndot.
stomach cancer .cndot. ovary cancer .cndot. corpus uteri cancer NSE
10 ng/ml or neuroblast tumor .cndot. lung small less cell cancer
.cndot. breast cancer .cndot. ovary cancer .cndot. esophagus cancer
.cndot. stomach cancer .cndot. pancreas cancer .cndot. large
intestine cancer .cndot. thyroid gland cancer .cndot. melanocytoma
.cndot. gastrinoma .cndot. insulinoma .cndot. carcinoid PAP 30.
ng/ml or prostate cancer less PIPC 160 ng/ml or bone metastasis of
prostate less cancer PIVKA-.quadrature. less than cell cancer 40
mAU/ml PSA 3.5 ng/ml or prostate cancer less PTH P 1.1 pmol/l or
malignant tumor accompanying less hypercalcemia .cndot. adult T
cell leukemia SCC 1.5 ng/ml or cervix uteri cancer .cndot. vagina
less cancer .cndot. vulva cancer .cndot. skin cancer .cndot.
esophagus cancer .cndot. lung cancer .cndot. upper airway cancer
.cndot. head and neck cancer .cndot. teratoma .cndot. bladder
cancer sICAM-1 75 U or less pancreas cancer .cndot. gallbladder
cancer .cndot. stomach cancer .cndot. cell leukemia .cndot. ATL SLX
38 U/ml or lung cancer .cndot. pancreas cancer .cndot. less biliary
tract cancer .cndot. ovary cancer .cndot. esophagus cancer .cndot.
stomach cancer .cndot. large intestine cancer .cndot. liver cancer
.cndot. uterine cancer r-Sm 4.0 ng/ml or prostate cancer less SP1
4.0 ng/ml or chorionic cancer .cndot. ovary cancer .cndot. less
testis tumor .cndot. lung cancer .cndot. breast cancer .cndot.
digestive system cancer SOD 150 ng/ml or ovary cancer .cndot. liver
cancer .cndot. less stomach cancer .cndot. leukemia Span-1 30 U/ml
or pancreas cancer .cndot. biliary tract less cancer .cndot. liver
cell cancer .cndot. stomach cancer .cndot. large intestine cancer
.cndot. esophagus cancer .cndot. lung cancer .cndot. malignant
lymphoma STN 45 U/ml or ovary cancer .cndot. stomach cancer .cndot.
less large intestine cancer .cndot. pancreas cancer .cndot. lung
cancer TK activity 5 U/I or less acute myelocytic leukemia .cndot.
acute lymphatic leukemia .cndot. malignant lymphoma .cndot.
malignant tumor TPA 70 U/I breast cancer .cndot. lung cancer
.cndot. stomach cancer .cndot. large intestine cancer .cndot.
primary liver cancer .cndot. biliary tract cancer .cndot. pancreas
cancer .cndot. bladder cancer .cndot. prostate cancer .cndot.
testis cancer .cndot. ovary cancer .cndot. cervix uteri cancer
.cndot. thyroid gland cancer .cndot. sarcoma .cndot. malignant
melanoma .cndot. lymphoma .cndot. leukemia YH-206 25 U/ml or
pancreas cancer .cndot. stomach cancer less Elastase 1 400 ng/ml or
pancreas cancer less Cytokeratin 3.5 ng/ml or lung cancer .cndot.
esophagus cancer .cndot. 19 fragment less rectum cancer .cndot.
ovary cancer .cndot. lung cancer .cndot. corpus uteri cancer
thyroid gland cancer Thyroglobulin 5-30 ng/ml thyroid gland cancer
CYFRA21-1 2.0 ng/ml lung squamous epithelium cancer .cndot.
esophagus cancer .cndot. stomach cancer .cndot. large intestine
cancer .cndot. ovary cancer .cndot. liver cancer .cndot. uterine
cancer
Example 1
Transverse Colon Cancer
[0154] In the present example, Mr. TM (76 year old) suffering from
transverse colon cancer was treated as follows, and course of
transverse colon cancer was observed. The body weight at treatment
initiation was 62 kg.
[0155] (Formulation)
[0156] A Celanese (haloperidol) 0.75 mg tablet was administered
before bedtime at 1/2 tablet a day.
[0157] 6.0 g of CPG (containing 1200 mg of ascorbic acid, and 18 mg
of calcium pantothenate) was administered on an empty stomach.
[0158] At hospitalization, 500 ml of an Aldofed injection solution
(maltose, potassium chloride, magnesium chloride, potassium
hydrogen phosphate, potassium dihydrogen phosphate, sodium
chloride, magnesium chloride (hexahydrate), anhydrous sodium
acetate, maltose (monohydrate)) was infused at decreased
appetite.
[0159] At reduction in blood potassium, SSR1 (Luvox (fluvoxamine
maleate, 25 mg) two tablets) was administered.
[0160] At anemia, 1 to 2 tablets of Ferromia (sodium ferrous
citrate) was administered on an empty stomach.
(Course)
[0161] When a test was performed before operation, the following
test results were obtained, and the patient was diagnosed to have
transverse colon cancer 15 days before the operation. Before 4
months from operation
CEA 2.7 (standard value is 5.0 or less) Ca19-9 (EIA) 19 (standard
value is 37 or less) Ca50 32 (standard value is 40 or less) Before
15 days from operation CEA 16.2 (standard value is 5.0 or less)
Ca19-9 (EIA) 128 (standard value is 37 or less) Ca50 96 (standard
value is 40 or less)
[0162] (Operation)
[0163] The size was 11.times.6 cm around 3/4 of transverse colon,
being Stage 4. A cancer was metastasized to mesentery lymph gland
S-shape colon and the like.
[0164] Forty-two cm around transverse colon cancer was all
isolated, and excised, mesentery was also excised as much as
possible, and colon node jobs were anastomosed. 200 ml of stored
blood was infused.
[0165] (After Operation)
[0166] The body weight at a normal time was 70 kg, while the body
weight was decreased to 49 kg after operation. Cancer markers were
all (-). Anemia was observed.
[0167] (Treatment)
[0168] Vitamin C, Celanese, and Luvox (25) were initiated 5 days
after operation.
[0169] (Course of 3 Months Post-Operation Examination)
[0170] S-shaped colon metastasized cancer disappeared. There was no
abnormality of blood, and markers were (-). Anemia was not
observed.
[0171] (Prognosis)
[0172] Also after cure, equal amounts of Vitamin C, Celanese, and
Luvox (25) were administered and, after 3 years from operation,
course is good.
Example 2
Treatment of Large Intestine Cancer Patient
[0173] Next, treatment of 11 large intestine cancer patients is
described.
[0174] (Treatment Method)
[0175] In principle, the same as Example 1.
[0176] (Case and Results)
[0177] The following is course of treatment of the large intestine
cancer patients.
TABLE-US-00002 TABLE 2 Dosing Anti- treatment Alive Birth Age/
Disease cancer at this or ID date Year name treatment time dead HS
Jan. 21, 1936 69 Large Lung 21 years Alive intestine metastasis
cancer (OP) TM Jun. 20, 1926 79 Large OP 5 Alive intestine cancer
MK Mar. 21, 1945 60 Large 4 years 4 years Dead intestine after OP,
cancer dosing was stopped. Dead at 10 months at Yoga. HH Mar. 31,
1919 86 Large OP 7 years Dead intestine cancer SN Apr. 30, 1914 91
Large 8 Years Dead intestine cancer MN Apr. 12, 1915 90 Large 8
Years Dead intestine cancer CH Jun. 11, 1931 73 Large C only 6
Alive intestine years cancer TY Dec. 11, 1952 52 Large OP 11 Years
Alive intestine Impossible cancer to completely excise ( ) KY Sep.
22, 1939 65 Large OP II 6 Years Alive intestine Japanese cancer Red
Cross Uterine cancer MK Jun. 21, 1919 86 Large 6 Years Alive
intestine cancer Trans- verse colon cancer
[0178] (Findings)
[0179] In all cases, patients were still alive unexpectedly, or in
dead cases, the life was remarkably prolonged as compared with the
previously announced life.
Example 3
Treatment of Liver Cancer Patients
[0180] Next, treatment of 7 liver cancer patients is described.
[0181] (Treatment Method)
[0182] In principle, the same as Example 1.
[0183] (Case and Results)
[0184] The following is the course of treatment of the
patients.
TABLE-US-00003 TABLE 3 Dosing Anti- treatment Alive Birth Age/
Disease cancer at this or ID date Year name treatment time dead SK
Jan. 2, 1933 72 Liver 8 years Alive cancer SK Mar. 29, 1935 70
Liver 4 months Alive cancer FS Aug. 8, 1942 62 Liver cancer TF Jan.
6, 1933 72 Liver cancer KM Aug. 20, 1926 79 Liver 15 years Alive
cancer HI Jan. 28, 1925 80 Liver 12 years Dead cancer SH Oct. 11,
1912 92 Liver 13 years Dead cancer
[0185] (Findings)
[0186] In all cases, patients were still alive unexpectedly, or in
dead cases, the life was remarkably prolonged as compared with the
previously announced life.
Example 4
Treatment of Prostate Cancer Patients
[0187] Next, treatment of 6 prostate cancer patients is
described.
[0188] (Treatment Method)
[0189] In principle, the same as Example 1.
(Case and Results)
[0190] The following is the course of treatment of the
patients.
TABLE-US-00004 TABLE 4 Dosing Anti- treatment Alive Birth Age/
Disease cancer at this or ID date Year name treatment time dead JI
78 Prostate 3 Years Alive cancer MK Apr. 20, 1916 89 Prostate
Bladder 6 Years Dead cancer metastasis Use of anti-cancer agent
Complete disappear- ance (Japan Baptist Hospital, change of doctor
Interruption Dead after 12 days) AK Aug. 7, 1927 77 Prostate 7
Years Alive cancer KN Feb. 9, 1931 74 Prostate 5 Years Alive cancer
MM Feb. 5, 1922 83 Prostate 3 Years Dead cancer NH May 22, 1947 58
Prostate 5 Years cancer
[0191] (Findings)
[0192] In all cases, patients were still alive unexpectedly, or in
dead cases, the life was remarkably prolonged as compared with the
previously announced life.
Example 5
Treatment of Lung Cancer Patients
[0193] Next, treatment of 5 lung cancer patients is described.
[0194] (Treatment Method)
[0195] In principle, the same as Example 1.
[0196] (Case and Results)
[0197] Course of treatment of patients is not described due to
personal reasons.
[0198] (Findings)
[0199] In all cases, patients were still alive unexpectedly, or in
dead cases, the life was remarkably prolonged as compared with the
previously announced life.
Example 6
Treatment of Breast Cancer Patients
[0200] Next, treatment of 5 breast cancer patients is
described.
[0201] (Treatment Method)
[0202] In principle, the same as Example 1.
[0203] (Case and Results)
[0204] Course of treatment of the patients is not described due to
personal reasons.
[0205] (Findings)
[0206] In all cases, patients were still alive unexpectedly, or in
dead cases, the life was remarkably prolonged as compared with the
announced life.
Example 7
Treatment of Stomach Cancer Patients
[0207] Next, treatment of 5 stomach cancer patients is
described.
[0208] (Treatment Method)
[0209] In principle, the same as Example 1.
[0210] (Case and Results)
[0211] The following is the course of treatment of a part of the
patients.
TABLE-US-00005 TABLE 5 Dosing Anti- treatment Alive Birth Age/
Disease cancer at this or ID date Years name treatment time dead MM
78 Stomach OP none Dead cancer KH Aug. 26, 1939 65 Stomach OP none
Alive cancer MY Sep. 30, 1929 76 Stomach 2 years 2 Alive cancer
months FN Feb. 21, 1964 41 Stomach cancer
[0212] (Findings)
[0213] In all cases, patients were still alive unexpectedly, or in
dead cases, the life was remarkably prolonged as compared with the
previously announced life.
Example 8
Treatment of Bladder Cancer Patients
[0214] Next, treatment of 3 bladder cancer patients is
described.
[0215] (Treatment of Method)
[0216] In principle, the same as Example 1.
[0217] (Case and Results)
[0218] The following is the course of treatment of the
patients.
TABLE-US-00006 TABLE 6 Dosing Anti- treatment Alive Birth Age/
Disease cancer at this or ID date Year name treatment time dead TN
Sep. 26, 1933 71 Bladder 15 Years Alive cancer HH Sep. 16, 1939 65
Bladder 12 Years Alive cancer HH- Feb. 25, 1924 81 Bladder none
Dead 2 cancer
[0219] (Findings)
[0220] In all cases, patients were still alive unexpectedly, or in
dead cases, the life was remarkably prolonged as compared with the
previously announced life.
Example 9
Treatment of Pancreas Cancer Patient
[0221] Next, treatment of one pancreas cancer patient is
described.
[0222] (Treatment Method)
[0223] In principle, the same as Example 1.
[0224] (Case and Results)
[0225] Course of treatment of the patient is not described due to
personal reasons.
[0226] (Findings)
[0227] In this case, the life was remarkably prolonged as compared
with the previously announced life, in a dead case.
Example 10
Treatment of Testis Cancer Patient
[0228] Next, treatment of one testis cancer patient is
described.
[0229] (Treatment Method)
[0230] In principle, the same as Example 1.
[0231] (Case and Results)
[0232] The following is the course of treatment of the patient.
TABLE-US-00007 TABLE 6 Dosing Anti- treatment Alive Birth Age/
Disease cancer at this or ID date Years name treatment time dead KM
Sep. 24, 1961 43 Testis 6 years 3 dead cancer months
[0233] (Findings)
[0234] In this case, the life was remarkably prolonged as compared
with the previously announced life, in a dead case.
Example 11
Treatment of Uterine Cancer Patients
[0235] Next, treatment of 2 uterine cancer patients is
described.
[0236] (Treatment of Method)
[0237] In principle, the same as Example 1.
[0238] (Case and Results)
[0239] The following is the course of treatment of the
patients.
TABLE-US-00008 TABLE 7 Dosing Anti- treatment Alive Birth Age/
Disease cancer at this or ID date Years name treatment time dead HY
May 25, 1917 88 Uterine 15 years Alive cancer KY Sep. 22, 1939 65
Large OP II Japan 6 years Alive intestine Red Cross cancer Uterine
cancer
[0240] (Findings)
[0241] In these cases, patients are still alive unexpectedly.
Example 12
Treatment of Pharyngeal Cancer Patients
[0242] Next, treatment of 2 pharyngeal cancer patients is
described.
[0243] (Treatment Method)
[0244] In principle, the same as Example 1.
[0245] (Case and Results)
[0246] Course of treatment of patients is not described due to
personal reasons.
[0247] (Findings)
[0248] In all cases, patients were still alive unexpectedly, or in
dead cases, the life was remarkably prolonged as compared with the
previously announced life.
Example 13
Treatment of Myelocystic Leukemia Patient
[0249] Next, treatment of one myelocystic leukemia patient is
described.
[0250] (Treatment of Method)
[0251] In principle, the same as Example 1.
[0252] (Case and Results)
[0253] The following is the course of treatment of the patient.
TABLE-US-00009 TABLE 8 Dosing Anti- treatment Alive Birth Age/
Disease cancer at this or ID date Years name treatment time dead SN
Apr. 20, 1910 95 Bone- 16 Years Dead marrow cancer
[0254] (Findings)
[0255] In this case, the life was remarkably prolonged as compared
with the announced life in a death case.
Example 14
Treatment of Ovary Cancer Patients
[0256] Next, treatment of 2 ovary cancer patients is described.
[0257] (Treatment Method)
[0258] In principle, the same as Example 1.
[0259] (Case and Results)
[0260] The following is the course of treatment of the
patients.
TABLE-US-00010 TABLE 9 Dosing Anti- treatment Alive Birth Age/
Disease cancer at this or ID date Years name treatment time dead FK
Dec. 13, 1943 61 Ovary 10 Years Alive cancer AM 79 Ovary 15 Years
Alive cancer KF Jun. 9, 1937 68 Ovary 1 year 1 Alive cancer month
TI Sep. 4, 1931 74 Ovary 10 years Alive cancer
[0261] (Findings)
[0262] In any case, the patients are still alive unexpectedly.
Example 15
Treatment of Rectum Cancer Patients
[0263] Next, treatment of 2 rectum cancer patients is descried.
[0264] (Treatment Method)
[0265] In principle, the same as Example 1.
[0266] (Case and Results)
[0267] The following is course of treatment of patients.
TABLE-US-00011 TABLE 10 Dosing Anti- treatment Alive Birth Age/
Disease cancer at this or ID date Years name treatment time dead IN
Nov. 24, 1928 76 Rectum 13 Years Alive cancer SN Apr. 19, 1922 83
Rectum 17 Years Dead cancer
[0268] (Findings)
[0269] In all cases, patients were still alive unexpectedly, or in
dead cases, the life was remarkably prolonged as compared with the
announced life.
Example 16
Treatment of Kidney Cancer Patients
[0270] Next, treatment of 2 kidney cancer patients is
described.
[0271] (Treatment Method)
[0272] In principle, the same as Example 1.
[0273] (Case and Results)
[0274] The following is course of treatment of the patients.
TABLE-US-00012 TABLE 11 Dosing Anti- treatment Alive Birth Age/
Disease cancer at this or ID date Years name treatment time dead TM
Oct. 28, 1951 53 Left 12 Years Alive kidney cancer
[0275] (Findings)
[0276] Also in this case, the patient is still alive
unexpectedly.
Example 17
Treatment of Muscular Dystrophy Patient
[0277] Next, treatment of one muscular dystrophy cancer patient is
described.
[0278] (Treatment Method)
[0279] In principle, the same as Example 1.
[0280] (Case and Results)
[0281] The following is the course of treatment of the patient.
TABLE-US-00013 TABLE 12 Dosing Anti- treatment Alive Birth Age/
Disease cancer at this or ID date Years name treatment time dead JM
Jul. 11, 1973 32 Muscular Part time 2 years 6 Alive dystrophy job
is months possible
[0282] (Findings)
[0283] Also in this case, the patient is still alive
unexpectedly.
Example 18
Treatment of Huntington's Chorea Patient
[0284] Next, treatment of one Huntington's chorea patient is
described.
[0285] (Treatment Method)
[0286] In principle, the same as Example 1.
(Case and Results)
[0287] The following is the course of treatment of the patient.
TABLE-US-00014 TABLE 13 Dosing Anti- treatment Alive Birth Age/
Disease cancer at this or ID date Years name treatment time dead TO
Oct. 4, 1938 77 Huntington' s Ordinary 12 Years Alive chorea
working
[0288] (Findings)
[0289] Also in this case, the patient is still alive
unexpectedly.
Example 19
Treatment of Spinocerebellar Degeneration Patients
[0290] Next, treatment of 2 spinocerebellar degeneration patients
is described.
[0291] (Treatment Method)
[0292] In principle, the same as Example 1.
[0293] (Case and Results)
[0294] The following is the course of treatment of the
patients.
TABLE-US-00015 TABLE 14 Dosing Anti- treatment Alive Birth Age/
Disease cancer at this or ID date Years name treatment time dead YS
Jan. 31, 1947 58 Spinocere- 1 year 4 Alive bellar months degener-
ation NH Jun. 11, 1954 51 Spinocere- 1 year 2 Alive bellar months
degener- ation
[0295] (Findings)
[0296] In any case, the patients are still alive unexpectedly.
Example 20
Treatment of Patients with Other Diseases
[0297] Next, treatment of patients with other diseases will be
described.
[0298] It is shown that this treatment is also effective in other
diseases.
[0299] As described above, the present invention has been
exemplified using preferable embodiments of the present invention,
but it is understood that the scope of the present invention is
construed only by claims. It is understood that contents of
patents, patent applications and literatures cited in the present
invention should be incorporated into the present specification by
reference as if the contents thereof were specifically described in
the specification.
INDUSTRIAL APPLICABILITY
[0300] The present invention exerts such an effect that almost all
diseases can be treated by a simple combination of two or more
kinds of drugs which have been previously used.
[0301] Since a patient can receive treatment under a condition mild
to the patient, the present invention can exert the maximum
therapeutic effect while loss of bodily strength of a patient is
extremely suppressed, and can avoid an unexpected side effect.
[0302] The present invention has large applicability in drug
industries such as production of drugs for realizing the
aforementioned therapy.
* * * * *